-+ 0.00%
-+ 0.00%
-+ 0.00%

Sonic Incytes Medical Announces Multi-Year Partnership With Madrigal Pharma To Advance Assessment And Risk Stratification Of Patients With Or At Risk For MASH

Benzinga·11/19/2026 13:12:59
Listen to the news

Partnership aims to help more clinicians assess and risk-stratify patients with or at risk for metabolic dysfunction-associated steatohepatitis (MASH), using point-of-care liver assessment.

Sonic Incytes Medical Corp., developer of the Velacur™ point-of-care liver assessment platform, today announced a multi-year partnership with Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for MASH, to advance the assessment and risk stratification of patients with or at risk for MASH.